RPL11P4: A Potential Drug Target and Biomarker (G100271272)

Target Name: RPL11P4

NCBI ID: G100271272

RPL11P4

Other Name(s): Ribosomal protein L11 pseudogene 4 | RPL11_2_1080 | ribosomal protein L11 pseudogene 4

RPL11P4: A Potential Drug Target and Biomarker

RPL11P4 is a gene located on chromosome 11q22. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The RPL11P4 gene is associated with the development and progression of various diseases, including ALZHEIMER'S DISEASE, Parkinson's disease, and WILSON'S DISEASE.

The RPL11P4 gene is expressed in various tissues and cells of the body, including brain, spinal cord, and peripheral tissues. It is a non-coding RNA gene that encodes a protein known as RPL11P4. The RPL11P4 protein is involved in various cellular processes, including cell adhesion, migration, and survival.

Research has shown that RPL11P4 is involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is thought to contribute to the development of these diseases by promoting the growth and survival of cancer cells, and by contributing to the neurodegeneration and immune dysfunction that occurs in these conditions.

One of the promising aspects of RPL11P4 is its potential as a drug target. By blocking the activity of RPL11P4, researchers may be able to reduce the growth and survival of cancer cells, and may be able to slow down or reverse the neurodegeneration and immune dysfunction that occurs in these conditions. This could lead to a more effective treatment for a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, RPL11P4 has also been identified as a potential biomarker for several diseases. The expression of RPL11P4 has been shown to be associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that RPL11P4 may be a useful biomarker for these conditions.

Research is ongoing to determine the full extent of RPL11P4's involvement in disease development and progression. Further studies are needed to fully understand the role of RPL11P4 in these conditions, and to identify its potential as a drug target and biomarker.

In conclusion, RPL11P4 is a gene that has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand its role in disease development and progression. If its potential as a drug target and biomarker is confirmed, RPL11P4 may be a valuable tool for the treatment of a range of diseases.

Protein Name: Ribosomal Protein L11 Pseudogene 4

The "RPL11P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL11P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets